These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8571286)

  • 1. [Pharmacovigilance seen by a selected group of general practitioners and of residents in the Midi-Pyrénées region].
    Pouget-Zago P; Lapeyre-Mestre M; Bagheri H; Montastruc JL
    Therapie; 1995; 50(5):459-62. PubMed ID: 8571286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug vigilance: opinion survey among residents of a university hospital].
    Graille V; Lapeyre-Mestre M; Montastruc JL
    Therapie; 1994; 49(5):451-4. PubMed ID: 7855763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Iatrogenic medication: estimation of its prevalence in French public hospitals. Regional Centers of Pharmacovigilance].
    Imbs JL; Pouyanne P; Haramburu F; Welsch M; Decker N; Blayac JP; Bégaud B
    Therapie; 1999; 54(1):21-7. PubMed ID: 10216418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
    Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
    Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adverse effects of locally applied drugs].
    Bagheri H; Frelezeau F; Montastruc JL
    Therapie; 2000; 55(1):211-9. PubMed ID: 10860026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Follow-up of 'medications and pregnancy' at the Midi-Pyrenees Pharmacovigilance Center'].
    Lemoine T; Lacroix I; Lapeyre-Mestre M; Montastruc JL; Damase-Michel C
    Therapie; 2001; 56(3):287-93. PubMed ID: 11475810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adverse drug effect notifications by nurses and comparison with cases reported by physicians].
    Sacilotto K; Bagheri H; Lapeyre-Mestre M; Montastruc JL; Montastruc P
    Therapie; 1995; 50(5):455-8. PubMed ID: 8571285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacovigilance of self-medication].
    Montastruc JL; Bagheri H; Geraud T; Lapeyre-Mestre M
    Therapie; 1997; 52(2):105-10. PubMed ID: 9231503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [French pharmacovigilance database system: examples of utilisation].
    Moore N; Noblet C; Kreft-Jais C; Lagier G; Ollagnier M; Imbs JL
    Therapie; 1995; 50(6):557-62. PubMed ID: 8745956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inter-regional differences in dysthyroidism due to amiodarone: comparison of spontaneous notifications in Aquitaine, Midi-Pyrenees and Languedoc-Roussillon].
    Bagheri H; Lapeyre-Mestre M; Levy C; Haramburu F; Hillaire-Buys D; Blayac JP; Montastruc JL
    Therapie; 2001; 56(3):301-6. PubMed ID: 11475812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction.
    Cornelissen L; van Puijenbroek E; van Grootheest K
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):76-81. PubMed ID: 17987591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance.
    Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
    Comput Biol Med; 2006; 36(7-8):748-67. PubMed ID: 16185681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Documentation and evaluation of adverse drug reactions (ADR)--contribution from a poison information center.
    Mey C; Hentschel H; Hippius M; Balogh A
    Int J Clin Pharmacol Ther; 2002 Mar; 40(3):102-7. PubMed ID: 11911597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of the capture-recapture method to assess the frequency of "serious" adverse drug reactions: experience of Toulouse University Hospital].
    Montastruc JL; Lugardon S; Desboeuf K; Fernet P; Lapeyre-Mestre M
    Bull Acad Natl Med; 2008 Feb; 192(2):421-30; discussion 430-1. PubMed ID: 18819693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme.
    Bracchi RC; Houghton J; Woods FJ; Thomas S; Smail SA; Routledge PA
    Br J Clin Pharmacol; 2005 Aug; 60(2):221-3. PubMed ID: 16042677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug related hospital admissions in subspecialities of internal medicine.
    Hallas J
    Dan Med Bull; 1996 Apr; 43(2):141-55. PubMed ID: 8741207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving medication safety: influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners.
    Roughead E; Pratt N; Peck R; Gilbert A
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):797-803. PubMed ID: 17476702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits].
    Durrieu G; Jacquot J; Baudrin D; Mège M; Rousseau V; Bagheri H; Bondon-Guitton E; Abadie D; Montastruc F; Bismuth M; Oustric S; Montastruc JL
    Therapie; 2017 Jun; 72(3):351-355. PubMed ID: 27865436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Satisfaction of a pharmacovigilance declaration support network in general practice].
    Driot D; Figuet L; Birebent J; Coste S; Durrieu G; Jacquot J; Bismuth M
    Therapie; 2018 Dec; 73(6):483-493. PubMed ID: 29921459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.